SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brody H. Medicine's ethical responsibility for health care reform—the Top Five list. N Engl J Med 2010;362:2835.
  • 2
    Cassel CK, Guest JA. Choosing Wisely: helping physicians and patients make smart decisions about their care. JAMA 2012;307:18012.
  • 3
    ABIM Foundation. Choosing Wisely lists. URL: http://www.choosingwisely.org/doctor-patient-lists.
  • 4
    Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, et al, and the American College of Rheumatology Core Membership Group.Choosing Wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question. Arthritis Care Res (Hoboken) 2013;65:32939.
  • 5
    Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006;129:17481.
  • 6
    Wong KO, Bond K, Homik J, Ellsworth JE, Karkhaneh M, Ha C, et al.Antinuclear antibody, rheumatoid factor, and cyclic-citrullinated peptide tests for evaluating musculoskeletal complaints in children.Rockville (MD):Agency for Health Care Research and Quality;2012.
  • 7
    Cabral DA, Petty RE, Fung M, Malleson PN. Persistent antinuclear antibodies in children without identifiable inflammatory rheumatic or autoimmune disease. Pediatrics 1992;89:4414.
  • 8
    Deane PM, Liard G, Siegel DM, Baum J. The outcome of children referred to a pediatric rheumatology clinic with a positive antinuclear antibody test but without an autoimmune disease. Pediatrics 1995;95:8925.
  • 9
    McGhee JL, Burks FN, Sheckels JL, Jarvis JN. Identifying children with chronic arthritis based on chief complaints: absence of predictive value for musculoskeletal pain as an indicator of rheumatic disease in children. Pediatrics 2002;110:3549.
  • 10
    Malleson PN, Mackinnon MJ, Sailer-Hoeck M, Spencer CH. Review for the generalist: the antinuclear antibody test in children. When to use it and what to do with a positive titer. Pediatr Rheumatol Online J 2010;8:27.
  • 11
    Man A, Shojania K, Phoon C, Pal J, de Badyn MH, Pi D, et al. An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing. Clin Rheumatol 2013;32:6018.
  • 12
    Centers for Disease Control and Prevention. Lyme disease diagnosis and treatment.2013. URL: http://www.cdc.gov/lyme/diagnosistesting/index.html.
  • 13
    American College of Physicians.Guidelines for laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997;127:11068.
  • 14
    Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089134.
  • 15
    Qureshi MZ, New D, Zulqarni NJ, Nachman S. Overdiagnosis and overtreatment of Lyme disease in children. Pediatr Infect Dis J 2002;21:124.
  • 16
    Ley C, Le C, Olshen EM, Reingold AL. The use of serologic tests for Lyme disease in a prepaid health plan in California. JAMA 1994;271:4603.
  • 17
    Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63:46582.
  • 18
    Mason T, Reed AM, Nelson AM, Thomas KB, Patton A, Hoffman AD, et al. Frequency of abnormal hand and wrist radiographs at time of diagnosis of polyarticular juvenile rheumatoid arthritis. J Rheumatol 2002;29:22148.
  • 19
    Okkalides D, Fotakis M. Patient effective dose resulting from radiographic examinations. Br J Radiol 1994;67:56472.
  • 20
    Palmisani E, Solari N, Magni-Manzoni S, Pistorio A, Labo E, Panigada S, et al. Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease. Arthritis Rheum 2006;55:8439.
  • 21
    Magni-Manzoni S, Rossi F, Pistorio A, Temporini F, Viola S, Beluffi G, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum 2003;48:350917.
  • 22
    Magni-Manzoni S, Malattia C, Lanni S, Ravelli A. Advances and challenges in imaging in juvenile idiopathic arthritis. Nat Rev Rheumatol 2012;8:32936.
  • 23
    Clinical Affairs sub-committee of the BSPAR. Standards of care for children and young people with juvenile idiopathic arthritis.2009. URL: https://www.bspar.org.uk/DocStore/FileLibrary/PDFs/BSPAR%20Standards%20of%20Care%20for%20Juvenile%20Idiopathic%20Arthritis.pdf.
  • 24
    Australian Government. Clinical guideline for the diagnosis and management of juvenile idiopathic arthritis.2009. URL: http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp119-juvenile-arthritis.pdf.
  • 25
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:32846.
  • 26
    Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:62539.
  • 27
    American College of Rheumatology. Rheumatoid arthritis quality indicators. URL: http://www.rheumatology.org/practice/ clinical/quality/ra.asp.
  • 28
    Khanna D, Arnold EL, Pencharz JN, Grossman JM, Traina SB, Lal A, et al. Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis. Semin Arthritis Rheum 2006;35:21137.
  • 29
    Mason T, Reed AM, Nelson AM, Thomas KB. Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study. Ann Rheum Dis 2005;64:4913.
  • 30
    Ravelli A, Ioseliani M, Norambuena X, Sato J, Pistorio A, Rossi F, et al. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 2007;56:308795.
  • 31
    Van Rossum MA, Boers M, Zwinderman AH, van Soesbergen RM, Wieringa H, Fiselier TJ, et al, on behalf of the Dutch Juvenile Idiopathic Arthritis Study Group.Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. Arthritis Rheum 2005;52:286572.
  • 32
    Poznanski AK, Hernandez RJ, Guire KE, Bereza UL, Garn SM. Carpal length in children–a useful measurement in the diagnosis of rheumatoid arthritis and some congenital malformation syndromes. Radiology 1978;129:6618.
  • 33
    Yazici Y, Sokka T, Pincus T. Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009;35:7239.
  • 34
    Anink J, Dolman KM, Merlijn van den Berg J, van Veenendaal M, Kuijpers TW, van Rossum MA. Two-year outcome of juvenile idiopathic arthritis in current daily practice: what can we tell our patients?Clin Exp Rheumatol 2012;30:9728.
  • 35
    Malattia C, Damasio MB, Magnaguagno F, Pistorio A, Valle M, Martinoli C, et al. Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. Arthritis Rheum 2008;59:176472.
  • 36
    Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:76284.
  • 37
    Kitamura CR, Rohekar G, Bykerk VP, Carette S. Are the 2002 American College of Rheumatology guidelines for the management of rheumatoid arthritis being followed in Canada's largest academic rheumatology center?J Rheumatol 2007;34:218392.
  • 38
    Hammer GP, Seidenbusch MC, Regulla DF, Spix C, Zeeb H, Schneider K, et al. Childhood cancer risk from conventional radiographic examinations for selected referral criteria: results from a large cohort study. AJR Am J Roentgenol 2011;197:21723.
  • 39
    Hashkes PJ, Balistreri WF, Bove KE, Ballard ET, Passo MH. The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:222634.
  • 40
    Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989;32:67781.
  • 41
    Lahdenne P, Rapola J, Ylijoki H, Haapasaari J. Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy. J Rheumatol 2002;29:24425.
  • 42
    Kugathasan S, Newman AJ, Dahms BB, Boyle JT. Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J Pediatr 1996;128:14951.
  • 43
    Kocharla L, Taylor J, Weiler T, Ting TV, Luggen M, Brunner HI. Monitoring methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2009;36:28138.
  • 44
    Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004;31:25016.
  • 45
    Hawley DP, Camina N, Rangaraj S. British Isles survey of methotrexate monitoring practice during treatment of juvenile idiopathic arthritis. Semin Arthritis Rheum 2011;40:35864.e1–2.
  • 46
    Petty RE, Cassidy JT, Sullivan DB. Clinical correlates of antinuclear antibodies in juvenile rheumatoid arthritis. J Pediatr 1973;83:3869.
  • 47
    Ferraz MB, Goldenberg J, Hilario MO, Bastos WA, Oliveira SK, Azevedo EC, et al, and the Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology.Evaluation of the 1982 ARA lupus criteria data set in pediatric patients. Clin Exp Rheumatol 1994;12:837.
  • 48
    Ravelli A, Varnier GC, Oliveira S, Castell E, Arguedas O, Magnani A, et al. Antinuclear antibody–positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 2011;63:26775.
  • 49
    Cassidy J, Kivlin J, Lindsley C, Nocton J, Section on Rheumatology, Section on Ophthalmology.Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 2006;117:18435.
  • 50
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:12717.
  • 51
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.